BeiGene Company Profile (NASDAQ:BGNE)

About BeiGene (NASDAQ:BGNE)

BeiGene logoBeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BGNE
  • CUSIP: N/A
  • Web: www.beigene.com
Capitalization:
  • Market Cap: $3.35 billion
  • Outstanding Shares: 39,820,000
Average Prices:
  • 50 Day Moving Avg: $92.21
  • 200 Day Moving Avg: $92.21
  • 52 Week Range: $26.43 - $118.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.84
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $6.42 per share
  • Price / Book: 13.09
Profitability:
  • EBITDA: ($179,280,000.00)
  • Return on Equity: -65.85%
  • Return on Assets: -49.40%
Debt:
  • Debt-to-Equity Ratio: 0.57%
  • Current Ratio: 8.38%
  • Quick Ratio: 8.38%
Misc:
  • Average Volume: 317,690 shs.
  • Beta: -0.32
  • Short Ratio: 3.93
 

Frequently Asked Questions for BeiGene (NASDAQ:BGNE)

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings results on Wednesday, March, 22nd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $0.19. The firm earned $1 million during the quarter, compared to analyst estimates of $3.75 million. The company's quarterly revenue was down 78.6% on a year-over-year basis. During the same quarter last year, the firm earned ($3.05) earnings per share. View BeiGene's Earnings History.

When will BeiGene make its next earnings announcement?

BeiGene is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for BeiGene.

Where is BeiGene's stock going? Where will BeiGene's stock price be in 2017?

6 brokerages have issued 12 month target prices for BeiGene's stock. Their forecasts range from $58.00 to $120.00. On average, they anticipate BeiGene's stock price to reach $88.00 in the next year. View Analyst Ratings for BeiGene.

What are analysts saying about BeiGene stock?

Here are some recent quotes from research analysts about BeiGene stock:

  • 1. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (10/3/2017)
  • 2. Maxim Group analysts commented, "BeiGene reported 1Q17 results. The company spent $52.5M during the quarter. The increased operating expenses were driven by clinical expansion to pivotal studies. Net loss for the quarter was $50.6M or ($1.27) per share. BeiGene ended the period with $327M of liquidity on the balance sheet. We model rising R&D expenses with clinical advances." (5/11/2017)

Who are some of BeiGene's key competitors?

Who are BeiGene's key executives?

BeiGene's management team includes the folowing people:

  • John V Oyler, Chairman of the Board, Chief Executive Officer, Founder
  • Howard Liang Ph.D., Chief Financial Officer and Chief Strategy Officer
  • Wendy Yan, Senior Vice President, Head of Regulatory Affairs
  • Jason Yang M.D.Suffix is Ph.D., Senior Vice President, Head of Clinical Development
  • Timothy Y. Chen, Director
  • Donald W. Glazer, Director
  • Michael J. Goller, Director
  • Ranjeev Krishana, Director
  • Xiaodong Wang Ph.D., Director

When did BeiGene IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

Who owns BeiGene stock?

BeiGene's stock is owned by many different of institutional and retail investors. Top institutional investors include BAKER BROS. ADVISORS LP (23.60%) and CELGENE CORP (5.60%). Company insiders that own BeiGene stock include Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, John Oyler, Ruirong Yuan, Thomas Malley and Xiaodong Wang. View Institutional Ownership Trends for BeiGene.

How do I buy BeiGene stock?

Shares of BeiGene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BeiGene's stock price today?

One share of BeiGene stock can currently be purchased for approximately $84.03.


MarketBeat Community Rating for BeiGene (NASDAQ BGNE)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  237
MarketBeat's community ratings are surveys of what our community members think about BeiGene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BeiGene (NASDAQ:BGNE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $88.00 (4.72% upside)
Consensus Price Target History for BeiGene (NASDAQ:BGNE)
Price Target History for BeiGene (NASDAQ:BGNE)
Analysts' Ratings History for BeiGene (NASDAQ:BGNE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Morgan StanleyReiterated RatingOverweight$87.00 -> $95.00N/AView Rating Details
9/28/2017Maxim GroupReiterated RatingBuy -> Buy$77.00 -> $120.00LowView Rating Details
8/15/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$43.00 -> $86.00LowView Rating Details
8/7/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$81.00HighView Rating Details
7/6/2017Robert W. BairdBoost Price TargetOutperform$44.00 -> $58.00HighView Rating Details
6/1/2017William BlairReiterated RatingOutperformLowView Rating Details
10/7/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for BeiGene (NASDAQ:BGNE)
Earnings by Quarter for BeiGene (NASDAQ:BGNE)
Earnings History by Quarter for BeiGene (NASDAQ BGNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017$0.23N/AView Earnings Details
3/22/2017Q4($0.86)($1.05)$3.75 million$1.00 millionViewN/AView Earnings Details
11/10/2016Q316($0.78)($1.08)$1.88 millionViewN/AView Earnings Details
8/10/2016Q2($0.68)($0.73)$2.08 million$0.40 millionViewN/AView Earnings Details
5/11/2016Q1($0.05)($0.97)$0.70 millionViewN/AView Earnings Details
3/30/2016Q4($1.06)($3.05)$1.74 million$4.68 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BeiGene (NASDAQ:BGNE)
2017 EPS Consensus Estimate: ($3.91)
2018 EPS Consensus Estimate: ($4.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($1.20)($1.20)($1.20)
Q3 20171($1.49)($1.49)($1.49)
Q4 20171($1.22)($1.22)($1.22)
Q1 20181($1.32)($1.32)($1.32)
Q2 20181($1.39)($1.39)($1.39)
Q3 20181($1.47)($1.47)($1.47)
Q4 20181($0.42)($0.42)($0.42)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BeiGene (NASDAQ:BGNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BeiGene (NASDAQ:BGNE)
Insider Ownership Percentage: 19.90%
Institutional Ownership Percentage: 51.02%
Insider Trades by Quarter for BeiGene (NASDAQ:BGNE)
Institutional Ownership by Quarter for BeiGene (NASDAQ:BGNE)
Insider Trades by Quarter for BeiGene (NASDAQ:BGNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2017Bros. Advisors Lp BakerDirectorBuy176,056$71.00$12,499,976.00View SEC Filing  
7/12/2017Xiaodong WangDirectorSell20,000$72.44$1,448,800.00View SEC Filing  
7/10/2017Donald W GlazerDirectorSell10,810$72.15$779,941.50View SEC Filing  
7/6/2017John OylerCEOSell219,400$64.82$14,221,508.00View SEC Filing  
6/28/2017Xiaodong WangDirectorSell35,000$44.95$1,573,250.00View SEC Filing  
6/23/2017John OylerCEOSell98,500$44.16$4,349,760.00View SEC Filing  
6/2/2017Xiaodong WangDirectorSell5,539$40.00$221,560.00View SEC Filing  
5/4/2017Xiaodong WangDirectorSell14,461$40.80$590,008.80View SEC Filing  
5/1/2017John OylerCEOSell36,149$40.47$1,462,950.03View SEC Filing  
4/5/2017Xiaodong WangDirectorSell11,650$36.83$429,069.50View SEC Filing  
3/24/2017Xiaodong WangDirectorSell38,107$36.96$1,408,434.72View SEC Filing  
3/20/2017John OylerCEOSell31,989$39.39$1,260,046.71View SEC Filing  
3/10/2017Xiaodong WangDirectorSell36,892$39.89$1,471,621.88View SEC Filing  
3/6/2017John OylerCEOSell108,999$40.91$4,459,149.09View SEC Filing  
2/27/2017Xiaodong WangDirectorSell38,351$38.19$1,464,624.69View SEC Filing  
2/21/2017John OylerCEOSell64,963$40.55$2,634,249.65View SEC Filing  
11/23/2016Thomas MalleyDirectorBuy30,000$32.00$960,000.00View SEC Filing  
11/18/2016Bros. Advisors Lp BakerDirectorBuy1,760,495$32.00$56,335,840.00View SEC Filing  
9/28/2016Donald W GlazerDirectorSell41,463$30.66$1,271,255.58View SEC Filing  
9/27/2016Donald W GlazerDirectorSell47,149$29.61$1,396,081.89View SEC Filing  
9/23/2016Donald W GlazerDirectorSell36,443$31.02$1,130,461.86View SEC Filing  
9/21/2016Donald W GlazerDirectorSell67,252$31.42$2,113,057.84View SEC Filing  
2/8/2016Bros. Advisors Lp BakerDirectorBuy1,912,680$24.00$45,904,320.00View SEC Filing  
2/8/2016Howard LiangCFOBuy65,000$1.85$120,250.00View SEC Filing  
2/8/2016Ruirong YuanInsiderBuy130,000$1.85$240,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BeiGene (NASDAQ:BGNE)
Latest Headlines for BeiGene (NASDAQ:BGNE)
Source:
Loading headlines, please wait.

Social

Chart

BeiGene (BGNE) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.